Measuring biomarkers to assess the therapeutic effects of PPAR agonists?
The metabolic syndrome is defined as a clustering of cardiovascular risk factors with insulin resistance, including dyslipidemia, coagulation disturbances and hypertension. Activators of the peroxisome proliferator-activated receptors (PPARs) modulate several of the metabolic risk factors predisposing to atherosclerosis. Fibrates are hypolipidemic drugs acting through activation of PPARalpha, whereas glitazones are insulin sensitizers activating PPARgamma. In addition, these drugs exert pleiotropic anti-inflammatory actions. In this review, we will focus on the effects of fibrates and glitazones on biomarker modulation and their usefulness in the treatment of cardiovascular disease.
Chinetti-Gbaguidi
Giulia
G
Institut Pasteur de Lille, 1, Rue Calmette BP245, Lille, F-59019, France. giulia.chinetti@pasteur-lille.fr
Staels
Bart
B
D000818:Animals; D015415:Biomarkers / Q000378:metabolism*; D002318:Cardiovascular Diseases / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism; D002986:Clinical Trials as Topic; D002995:Clofibric Acid / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D024821:Metabolic Syndrome / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism; D047492:Peroxisome Proliferator-Activated Receptors / Q000819:agonists* / Q000235:genetics; D045162:Thiazolidinediones / Q000494:pharmacology / Q000627:therapeutic use*; D016896:Treatment Outcome
D015415:Biomarkers; D047492:Peroxisome Proliferator-Activated Receptors; D045162:Thiazolidinediones; D002995:Clofibric Acid